HC Wainwright & Co. Reiterates Buy Rating on Cytokinetics, Incorporated (CYTK)

Market Context

Cytokinetics, Incorporated operates in the Healthcare sector. The stock currently trades at $62.43 with a market capitalization of $7.2B. The stock has gained 5.1% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Cytokinetics, Incorporated.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Cytokinetics, Incorporated

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 19, 2026	HC Wainwright & Co.	Buy	N/A
Oct 16, 2026	William Blair	Outperform	N/A
Oct 08, 2026	RBC Capital	Outperform	N/A
Aug 31, 2026	HC Wainwright & Co.	Buy	N/A
Aug 13, 2026	JP Morgan	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View CYTK Stock Page